Skip to content

Released Nov 12, 2026, after the close

10-Q filed Nov 12, 2026, 43 days after period end · 0001193125-26-458441

Q3 2026 · 10-Q
Revenue$2.96M−72.6% vs Q3 2025−77.9% vs Q2 2026
Net Income-$20.26MN/M vs Q3 2025N/M vs Q2 2026
EPS Diluted-$0.93N/M vs Q3 2025N/M vs Q2 2026
Operating Income-$23,415,000N/M
Operating Cash Flowderived-$17,164,000N/M
Free Cash Flowderived-$17,285,000N/M
Margins · derived
Operating margin-792.1%−691.2 pt vs Q3 2025
Net margin-685.3%−600.0 pt vs Q3 2025

What the release said

On November 12, 2026, Assembly Biosciences, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2026.

Assembly Biosciences reported a net loss attributable to common stockholders of $20.3 million, or $0.93 per basic and diluted share, for the three months ended September 30, 2026, compared to $9.2 million, or $0.72 per share, for the same period in 2025.2

The company received a $75 million collaboration extension fee from Gilead and exercised its option to participate in a 40% share of U.S. development costs and profits for the HSV helicase primase inhibitor program.34

Revenue from collaborative research with Gilead was $3.0 million for the three months ended September 30, 2026, compared to $10.8 million for the same period in 2025.5

Cash, cash equivalents and marketable securities were $314.3 million as of September 30, 2026, compared to $320.4 million as of June 30, 2026, and are projected to fund operations into 2029.6

The company initiated dosing in a Phase 2 study evaluating ABI-6250 in participants with chronic hepatitis delta infection.7

Net loss attributable to common stockholders
$20.3 million Three months ended September 30, 2026; compared to $9.2 million for the same period in 20252
Net loss per basic and diluted share
$0.93 Three months ended September 30, 2026; compared to $0.72 per share for the same period in 20252
Revenue from collaborative research with Gilead
$3.0 million Three months ended September 30, 2026; compared to $10.8 million for the same period in 20255
Cash, cash equivalents and marketable securities
$314.3 million As of September 30, 2026; compared to $320.4 million as of June 30, 20266
Collaboration extension fee received from Gilead
$75 million Received following the third anniversary of the collaboration3
Thaler Agent · checked against the filing
Open the reading ›
The release

Same quarter

MetricQ3 2026Q3 2025Q3 2024Q3 2023
Revenue$2.96M$10.79M$6.85M$0.00
Net Income-$20.26M-$9.20M-$9.61M-$14.42M
EPS Diluted-$0.93-$0.72-$1.51-$3.29

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR